EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Helping Apo2L/TRAIL in the Battle: Synergistic Therapeutic Approaches for Cancer Therapies

Elena Valeria Fuior iD, Madalina Dumitrescu, Marius Gabriel Multescu iD, Bianca Sanziana Daraban, Madalin Ghinea iD, Oana Mirancea, George E D Petrescu iD, Felix Mircea Brehar, Ana Maria Vacaru iD, Radu Ionita iD, Violeta Georgeta Bivol, Irina Florina Tudorache und 4 weitere

International Journal of Molecular Sciences · 07.08.2026 · 27 (16) · 7068

DOI: 10.3390/ijms27167068 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 07.08.2026. Verfasst von Elena Valeria Fuior und 15 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Cellular Biology and Pathology "Nicolae Simionescu", Romanian Academy, 050568 Bucharest, Romania. Hauptthemen laut MEDLINE: TNF-Related Apoptosis-Inducing Ligand, Neoplasms. Die Arbeit nennt 220 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union (NextGenerationEU).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) selectively triggers apoptosis in malignant, infected, or stressed cells while sparing normal tissues, making it an attractive therapeutic candidate. However, many tumors exhibit intrinsic or acquired resistance to TRAIL, driven by reduced DR4/DR5 surface expression, elevated decoy receptor levels, dysregulated DISC assembly, overexpression of c-FLIP and anti-apoptotic Bcl-2 family proteins, or activation of survival pathways such as NF-κB, PI3K/Akt, and MAPK. Moreover, TRAIL receptors can initiate non-canonical signaling pathways that promote migration, invasion, and metastasis in specific oncogenic contexts, thereby further limiting therapeutic efficacy. We aimed to integrate mechanistic insights into TRAIL biology with current therapeutic advances, providing a comprehensive framework for understanding resistance and for designing rational TRAIL-based combination strategies. We summarized the structural and signaling features of TRAIL receptors, outlined the major determinants of TRAIL sensitivity, and evaluated predictive biomarkers that may guide patient selection. In addition, we examined next-generation TRAIL agonists and targeted delivery systems developed to enhance receptor clustering, pharmacokinetics, and tumor specificity. Together, these insights highlight the therapeutic promise of mechanistically informed TRAIL combinations. A deeper understanding of resistance pathways and biomarker-guided stratification will be essential for restoring apoptotic competence and improving clinical outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TNF-Related Apoptosis-Inducing LigandNeoplasmsHumansReceptors, TNF-Related Apoptosis-Inducing LigandAnimalsSignal TransductionApoptosisDrug Resistance, NeoplasmAntineoplastic Agents

Stichwörter der Autor:innen

TRAILapo2Lapoptosiscancercombinatorial therapydeath receptor

Substanzen

TNF-Related Apoptosis-Inducing LigandReceptors, TNF-Related Apoptosis-Inducing LigandTNFSF10 protein, humanAntineoplastic Agents

Autor:innen und Institutionen

  • Institute of Cellular Biology and Pathology "Nicolae Simionescu", Romanian Academy, 050568 Bucharest, Romania.
  • Neurosurgery Clinic, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.
  • Department of Neurosurgery, Bagdasar-Arseni Emergency Clinical Hospital, 041915 Bucharest, Romania.
  • Pharmacology Laboratory, Department of Medicine, University of Patras, 26504 Rio Achaias, Greece.

ORCID-Profile: Elena Valeria Fuior, Marius Gabriel Multescu, Madalin Ghinea, George E D Petrescu, Ana Maria Vacaru, Radu Ionita, Ioana Madalina Fenyo, Evangelia Zvintzou, Anca Violeta Gafencu

Förderung

  • European Union (NextGenerationEU)

Zitieren

APA

Fuior, E. V., Dumitrescu, M., Multescu, M. G., Daraban, B. S., Ghinea, M., Mirancea, O., Petrescu, G. E. D., Brehar, F. M., Vacaru, A. M., Ionita, R., Bivol, V. G., Tudorache, I. F., Popa, A., Fenyo, I. M., Zvintzou, E., & Gafencu, A. V. (2026). Helping Apo2L/TRAIL in the Battle: Synergistic Therapeutic Approaches for Cancer Therapies. International Journal of Molecular Sciences, 27(16), 7068. https://doi.org/10.3390/ijms27167068

Vancouver

Fuior EV, Dumitrescu M, Multescu MG, Daraban BS, Ghinea M, Mirancea O, et al. Helping Apo2L/TRAIL in the Battle: Synergistic Therapeutic Approaches for Cancer Therapies. International Journal of Molecular Sciences. 2026;27(16):7068. doi:10.3390/ijms27167068

BibTeX
@article{Fuior2026,
  author = {Fuior, Elena Valeria and Dumitrescu, Madalina and Multescu, Marius Gabriel and Daraban, Bianca Sanziana and Ghinea, Madalin and Mirancea, Oana and Petrescu, George E D and Brehar, Felix Mircea and Vacaru, Ana Maria and Ionita, Radu and Bivol, Violeta Georgeta and Tudorache, Irina Florina and Popa, Andreea and Fenyo, Ioana Madalina and Zvintzou, Evangelia and Gafencu, Anca Violeta},
  title = {Helping Apo2L/TRAIL in the Battle: Synergistic Therapeutic Approaches for Cancer Therapies},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {16},
  pages = {7068},
  doi = {10.3390/ijms27167068}
}
Kostenlos starten →